サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1427831

グライコミクス治療の世界市場レポート 2024

Glycomic Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
グライコミクス治療の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

グライコミクス治療の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には16.4%の年間複合成長率（CAGR）で3,010億3,000万米ドルに成長すると予想されます。予測期間の成長は、糖鎖生物学の理解の深まり、精密医療アプローチの採用、免疫療法への関心の高まり、希少疾患調査への資金提供の増加、糖鎖バイオマーカーの出現に起因すると考えられます。予測期間の主な動向には、腫瘍学におけるグライコミックの広範な応用、改善された治療用タンパク質のためのグライコミックエンジニアリング、免疫腫瘍学におけるグライコミックの統合、希少疾患および遺伝性疾患におけるグライコミックの利用、およびグライコミック医薬品の規制上の考慮事項が含まれます。

糖尿病の有病率の上昇により、グライコミクス治療市場の成長が促進されると予想されます。血糖（グルコース）レベルの調節に影響を与える慢性病状である糖尿病は、観察されるグリカンの変化と関連しており、インスリン抵抗性やその他の代謝異常の一因となります。独特の糖鎖パターンは、糖尿病の診断、進行の予測、治療に対する反応のモニタリングのためのバイオマーカーとして機能します。たとえば、国立保健統計センターの報告によると、2023年 5月の時点で、米国の18歳以上の成人で糖尿病と診断された人の割合は、2020年の9.3%から2021年の9.6%に増加しました。 グライコミクス治療の成長は、糖尿病の有病率の増加によって促進されています。

がんの発生率の増加により、グライコミクス治療市場の成長が促進される見込みです。制御されていない細胞の増殖と広がりを特徴とするがんには、治療におけるグライコミクス治療の応用が見られます。これらの治療薬は、細胞表面上の特定の糖分子を標的にして修飾し、重要な細胞相互作用、シグナル伝達経路、免疫応答に影響を与え、腫瘍の増殖を阻害し、がん治療の有効性を高めることを目的としています。たとえば、米国がん協会の報告によると、2023年の米国女性の新規肝臓がん推定症例数は、2022年の12,660人から2023年には13,230人に増加しました。したがって、がんの有病率の増加は、グライコミクス治療市場の成長を促進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のグライコミクス治療市場、クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 孤立した
  • 合成
  • 世界のグライコミクス治療市場、構造別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 糖タンパク質
  • シアル酸標的
  • プロテオグリカン
  • グリコサミノグリカン標的
  • グリコシルホスファチジルイノシトール（Gpi）アンカータンパク質およびヘパリンベースのグリカン
  • スフィンゴ糖脂質標的
  • その他
  • 世界のグライコミクス治療市場、作用機序別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ノイラミニダーゼ阻害
  • ヘパラナーゼとセレクチン阻害、成長因子とヘパラン硫酸間相互作用をブロック
  • エリスロポエチンおよび酵素補充療法（Ert）
  • 組織プラスミノーゲン活性化因子
  • グルコシルセラミド合成酵素阻害
  • インターロイキン1、2、3
  • ベータおよびガンマインターフェロン
  • その他
  • 世界のグライコミクス治療市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 血栓症と化学予防法
  • 貧血
  • 抗癒着性および抗炎症性
  • 白内障
  • ゴーシェ病
  • MPS-1およびIV
  • がん
  • アルツハイマー病
  • インフルエンザA型とB型
  • その他

第7章 地域および国の分析

  • 世界のグライコミクス治療市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のグライコミクス治療市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • グライコミクス治療市場の競合情勢
  • グライコミクス治療ス市場の企業プロファイル
    • F Hoffmann-La Roche Ltd.
    • Bayer AG
    • Sanofi SA
    • Thermo Fisher Scientific Inc.
    • GlaxoSmithKline plc

第31章 その他の大手および革新的な企業

  • Merck KGaA
  • ICON plc
  • Agilent Technologies Inc.
  • AMS Bio
  • Shimadzu Corporation
  • Waters Corporation
  • Bruker Corporation
  • BioMarin Pharmaceutical Inc.
  • Bio Techne Corp.
  • Promega Corporation
  • Halozyme Therapeutics Inc.
  • Takara Bio Inc.
  • Vector Laboratories
  • New England Biolabs Inc.
  • Protalix Biotherapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13675

Glycomic therapeutics involves the application of glycomics-based approaches in the field of therapeutic development. The glycome, which constitutes the complete set of glycans in a cell or organism, plays a crucial role in understanding the intricate nature of biological systems and their implications for health and disease. Glycans are involved in diverse biological processes, including cell signaling, immune responses, and the development of diseases.

The primary types of glycomic therapeutics fall into two classes isolated and synthetic. Isolated glycomic therapy focuses on the study and analysis of glycans in isolation, delving into the structural and functional characterization of individual glycan molecules. Synthetic glycomic therapy involves the use of artificially created glycans or glycan-based molecules for diagnosing and treating various diseases or medical conditions. These therapies target different structures such as glycoproteins, sialic acid, proteoglycans, glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins, heparin-based glycans, glycosphingolipids, and others. The mode of action varies, including inhibiting neuraminidase, heparanase, selectins, blocking interactions between growth factors and heparan sulfate, and applications in erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibiting glucosylceramide synthase, and targeting interleukins, interferons, among others. These therapies are employed for indications such as thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory purposes, cataracts, Gaucher's disease, MPS-1 and IV, cancer, Alzheimer's disease, influenza types A and B, and more.

The glycomic therapeutics market research report is one of a series of new reports from The Business Research Company that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $141.31 billion in 2023 to $163.73 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to a heightened understanding of the significance of glycans, an increase in chronic diseases, the development of drugs for rare diseases, and collaborative efforts in glycomics research.

The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $301.03 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to the increasing understanding of glycan biology, the adoption of precision medicine approaches, growing interest in immunotherapy, higher funding for rare diseases research, and the emergence of glycan biomarkers. Major trends in the forecast period include the broader applications of glycomics in oncology, glycoengineering for improved therapeutic proteins, the integration of glycomics in immuno-oncology, the utilization of glycomics in rare and genetic disorders, and regulatory considerations for glycomic drugs.

The rise in the prevalence of diabetes is anticipated to boost the growth of the glycomic therapeutics market. Diabetes, a chronic medical condition affecting the regulation of blood sugar (glucose) levels, is associated with observed alterations in glycans, contributing to insulin resistance and other metabolic abnormalities. Distinct glycan patterns function as biomarkers for diagnosing diabetes, predicting its progression, and monitoring responses to treatment. For instance, as of May 2023, according to a report from the National Center for Health Statistics, the percentage of diagnosed diabetes in adults aged 18 and over in the United States increased from 9.3% in 2020 to 9.6% in 2021. Therefore, the growth of glycomic therapeutics is driven by the increasing prevalence of diabetes.

The rising incidence of cancer is poised to drive the growth of the glycomic therapeutics market. Cancer, characterized by uncontrolled cell growth and spread, sees applications of glycomic therapeutics in treatment. These therapeutics target and modify specific sugar molecules on cell surfaces, influencing crucial cellular interactions, signaling pathways, and immune responses, with the goal of inhibiting tumor growth and enhancing the effectiveness of cancer therapies. For example, in 2023, the estimated number of new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, as reported by the American Cancer Society. Therefore, the increasing prevalence of cancer is a key factor driving the growth of the glycomic therapeutics market.

Product innovation stands out as a prominent trend gaining traction in the glycomic therapeutics market. Key players in the glycomic therapeutics sector are strategically investing in the development of cutting-edge technologies and innovative solutions to fortify their market position. For example, in April 2022, Glenmark Pharmaceuticals Limited, an Indian-based pharmaceutical company dedicated to discovering advanced therapies, introduced a novel fixed-dose combination (FDC) featuring a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This innovative combination aims to enhance glycemic control and reduce insulin resistance in patients with type 2 diabetes.

Leading companies in the glycomic therapeutics sector are actively engaged in the creation of groundbreaking technological solutions, such as screening kits, to advance glycobiology research and exploration. A screening kit is a pre-packaged set of tools and materials designed for a preliminary test to detect the presence or absence of a specific substance, condition, or property. For instance, in July 2022, Vector Laboratories, a US-based provider of glycomic solutions, launched Glysite Scout Glycan screening kits. These kits, fully integrated for immunofluorescence, facilitate the detection of glycan expression in tissue sections, allowing researchers to profile and characterize complex glycans in biological systems and identify major surface glycan motifs in a sample.

In May 2022, Halozyme Therapeutics, a US-based biotechnology company, completed the acquisition of Antares Pharma Inc. for $960 million. This strategic move bolstered Halozyme's pipeline portfolio of novel treatments utilizing advanced drug delivery methods, enhancing safety, efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc. is a US-based pharmaceutical firm.

Major companies operating in the glycomic therapeutics market report are F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline PLC, Merck KGaA, ICON PLC, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd., Z Biotech LLC, Alzheon Inc., GlycoMar Limited

North America was the largest region in the glycomic therapeutics in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glycomic Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glycomic therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glycomic therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glycomic therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Class: Isolated; Synthetic
  • 2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans; Targeting Glycosphingolipids; Other Structures
  • 3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons; Other Mode Of Action
  • 4) By Indications: Thrombosis And Chemoprophylaxis; Anemia; Anti-Adhesive And Anti-Inflammatory; Cataracts; Gaucher's Disease; Mps-1 And IV; Cancer; Alzheimer's Disease; Influenza Type A And B; Other Indications
  • Companies Mentioned: F Hoffmann-La Roche Ltd.; Bayer AG; Sanofi SA; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glycomic Therapeutics Market Characteristics

3. Glycomic Therapeutics Market Trends And Strategies

4. Glycomic Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Glycomic Therapeutics Market Size and Growth

  • 5.1. Global Glycomic Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Glycomic Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Glycomic Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Glycomic Therapeutics Market Segmentation

  • 6.1. Global Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Isolated
  • Synthetic
  • 6.2. Global Glycomic Therapeutics Market, Segmentation By Structures, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Glycoproteins
  • Targeting Sialic Acid
  • Proteoglycans
  • Targeting Glycosaminoglycans
  • Glycosylphosphatidylinositol (Gpi)-Anchored Proteins And Heparin Based Glycans
  • Targeting Glycosphingolipids
  • Other Structures
  • 6.3. Global Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Inhibits Neuraminidase
  • Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
  • Erythropoietin And Enzyme Replacement Therapy (Ert)
  • Tissue Plasminogen Activator
  • Inhibits Glucosylceramide Synthase
  • Interleukin 1, 2 And 3
  • Beta And Gamma Interferons
  • Other Mode Of Action
  • 6.4. Global Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Thrombosis And Chemoprophylaxis
  • Anemia
  • Anti-Adhesive And Anti-Inflammatory
  • Cataracts
  • Gaucher's Disease
  • Mps-1 And Iv
  • Cancer
  • Alzheimer's Disease
  • Influenza Type A And B
  • Other Indications

7. Glycomic Therapeutics Market Regional And Country Analysis

  • 7.1. Global Glycomic Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Glycomic Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Glycomic Therapeutics Market

  • 8.1. Asia-Pacific Glycomic Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Glycomic Therapeutics Market

  • 9.1. China Glycomic Therapeutics Market Overview
  • 9.2. China Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Glycomic Therapeutics Market

  • 10.1. India Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Glycomic Therapeutics Market

  • 11.1. Japan Glycomic Therapeutics Market Overview
  • 11.2. Japan Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Glycomic Therapeutics Market

  • 12.1. Australia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Glycomic Therapeutics Market

  • 13.1. Indonesia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Glycomic Therapeutics Market

  • 14.1. South Korea Glycomic Therapeutics Market Overview
  • 14.2. South Korea Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Glycomic Therapeutics Market

  • 15.1. Western Europe Glycomic Therapeutics Market Overview
  • 15.2. Western Europe Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Glycomic Therapeutics Market

  • 16.1. UK Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Glycomic Therapeutics Market

  • 17.1. Germany Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Glycomic Therapeutics Market

  • 18.1. France Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Glycomic Therapeutics Market

  • 19.1. Italy Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Glycomic Therapeutics Market

  • 20.1. Spain Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Glycomic Therapeutics Market

  • 21.1. Eastern Europe Glycomic Therapeutics Market Overview
  • 21.2. Eastern Europe Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Glycomic Therapeutics Market

  • 22.1. Russia Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Glycomic Therapeutics Market

  • 23.1. North America Glycomic Therapeutics Market Overview
  • 23.2. North America Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Glycomic Therapeutics Market

  • 24.1. USA Glycomic Therapeutics Market Overview
  • 24.2. USA Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Glycomic Therapeutics Market

  • 25.1. Canada Glycomic Therapeutics Market Overview
  • 25.2. Canada Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Glycomic Therapeutics Market

  • 26.1. South America Glycomic Therapeutics Market Overview
  • 26.2. South America Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Glycomic Therapeutics Market

  • 27.1. Brazil Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Glycomic Therapeutics Market

  • 28.1. Middle East Glycomic Therapeutics Market Overview
  • 28.2. Middle East Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Glycomic Therapeutics Market

  • 29.1. Africa Glycomic Therapeutics Market Overview
  • 29.2. Africa Glycomic Therapeutics Market, Segmentation By Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Glycomic Therapeutics Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Glycomic Therapeutics Market, Segmentation By Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Glycomic Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Glycomic Therapeutics Market Competitive Landscape
  • 30.2. Glycomic Therapeutics Market Company Profiles
    • 30.2.1. F Hoffmann-La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Bayer AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sanofi SA
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Thermo Fisher Scientific Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Glycomic Therapeutics Market Other Major And Innovative Companies

  • 31.1. Merck KGaA
  • 31.2. ICON plc
  • 31.3. Agilent Technologies Inc.
  • 31.4. AMS Bio
  • 31.5. Shimadzu Corporation
  • 31.6. Waters Corporation
  • 31.7. Bruker Corporation
  • 31.8. BioMarin Pharmaceutical Inc.
  • 31.9. Bio Techne Corp.
  • 31.10. Promega Corporation
  • 31.11. Halozyme Therapeutics Inc.
  • 31.12. Takara Bio Inc.
  • 31.13. Vector Laboratories
  • 31.14. New England Biolabs Inc.
  • 31.15. Protalix Biotherapeutics Inc.

32. Global Glycomic Therapeutics Market Competitive Benchmarking

33. Global Glycomic Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Glycomic Therapeutics Market

35. Glycomic Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Glycomic Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Glycomic Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Glycomic Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer